Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells

International Journal of Biochemistry and Molecular Biology

Volumn 1, Issue 1, 2010, Pages 1-11

  Ni, Zhanglin ^a   Mark, Michelle E ^a   Cai, Xiaokun ^a   Mao, Qingcheng ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ABCG2; And FRET; BCRP; Dimerization; Oligomerization

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYSTEINE; DIMER; MITOXANTRONE; OLIGOMER; YELLOW FLUORESCENT PROTEIN;

ANTIGEN BINDING; ARTICLE; CELL STRAIN HEK293; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIMERIZATION; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; OLIGOMERIZATION; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; WILD TYPE;

EID: 77958064707     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mao Q, and Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J 2005; 7:E118-E133.
2. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, and Bates SE. ABCG2: a perspective. Adv Drug Deliv Rev 2009; 61:3-13.
3. JT. Biochemistry and pharmacology of the human multidrug resistance gene product, ABCG2. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007; 32:531-541.
4. Robey RW, Polgar O, Deeken J, To KW, and Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007; 26:39-57.
5. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, and Sorrentino BP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A 2002; 99:12339-12344.
6. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, and Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7:1028-1034.
7. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61:3458-3464.
8. Cooray HC, Blackmore CG, Maskell L, and Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002; 13:2059-2063.
9. Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 2004; 64:3296-3301.
10. Wang H, Wu X, Hudkins K, Mikheev A, Zhang H, Gupta A, Unadkat JD, and Mao Q. Expression of the breast cancer resistance protein (Bcrp1/ Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am J Physiol Endocrinol Metab 2006; 291:E1295-1304.
11. Polgar O, Robey RW, and Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008; 4:1-15.
12. Sarkadi B, Homolya L, Szakacs G, and Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006; 86: 1179-1236.
13. Doyle L, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998; 95:15665-15670.
14. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, and Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone- resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59:8-13.
15. Kusuhara H, and Sugiyama Y. ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch 2007; 453:735-744.
16. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, and Sugimoto Y. Dominantnegative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 2002; 97:626-630.
17. Bhatia A, Schafer HJ, and Hrycyna CA. Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. Biochemistry 2005; 44:10893-10904.
18. Henriksen U, Fog JU, Litman T, and Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem 2005; 280:36926-36934.
19. Xu J, Liu Y, Yang Y, Bates S, and Zhang JT. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 2004; 279:19781-19789.
20. McDevitt CA, Collins RF, Conway M, Modok S, Storm J, Kerr ID, Ford RC, and Callaghan R. Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 2006; 14:1623-1632.
21. Xu J, Peng H, Chen Q, Liu Y, Dong Z, and Zhang JT. Oligomerization domain of the multidrug resistance- associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res 2007; 67:4373-4381.
22. Wang H, Lee EW, Cai X, Ni Z, Zhou L, and Mao Q. Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry 2008; 47:13778-13787.
23. Kage K, Fujita T, and Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci 2005; 96:866-872.
24. Wakabayashi K, Nakagawa H, Adachi T, Kii I, Kobatake E, Kudo A, and Ishikawa T. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J Exp Ther Oncol 2006; 5:205-222.
25. Liu Y, Yang Y, Qi J, Peng H, and Zhang JT. Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. J Pharmacol Exp Ther 2008; 326:33-40.
26. Fjorback AW, Pla P, Muller HK, Wiborg O, Saudou F, and Nyengaard JR. Serotonin transporter oligomerization documented in RN46A cells and neurons by sensitized acceptor emission FRET and fluorescence lifetime imaging microscopy. Biochem Biophys Res Commun 2009; 380:724-728.
27. Qu Q, and Sharom FJ. FRET analysis indicates that the two ATPase active sites of the Pglycoprotein multidrug transporter are closely associated. Biochemistry 2001; 40:1413-1422.
28. Weinglass AB, Swensen AM, Liu J, Schmalhofer W, Thomas A, Williams B, Ross L, Hashizume K, Kohler M, Kaczorowski GJ, and Garcia ML. A high-capacity membrane potential FRET-based assay for the sodium-coupled glucose co-transporter SGLT1. Assay Drug Dev Technol 2008; 6:255-262.
29. Hillebrand M, Verrier SE, Ohlenbusch A, Schafer A, Soling HD, Wouters FS, and Gartner J. Live cell FRET microscopy: homo- and heterodimerization of two human peroxisomal ABC transporters, the adrenoleukodystrophy protein (ALDP, ABCD1) and PMP70 (ABCD3). J Biol Chem 2007; 282:26997-27005.
30. Schmid JA, Scholze P, Kudlacek O, Freissmuth M, Singer EA, and Sitte HH. Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J Biol Chem 2001; 276:3805-3810.
31. Orban TI, Seres L, Ozvegy-Laczka C, Elkind NB, Sarkadi B, and Homolya L. Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter. Biochem Biophys Res Commun 2008; 367:667-673.
32. Ozvegy-Laczka C, Laczko R, Hegedus C, Litman T, Varady G, Goda K, Hegedus T, Dokholyan NV, Sorrentino BP, Varadi A, and Sarkadi B. Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J Biol Chem 2008; 283:26059-26070.
33. Vethanayagam RR, Wang H, Gupta A, Zhang Y, Lewis F, Unadkat JD, and Mao Q. Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N. Drug Metab Dispos 2005; 33:697-705.
34. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, and Bates SE. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001; 1512:171-182.
35. Gupta A, Zhang Y, Unadkat JD, and Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004; 310:334-341.
36. Ozvegy-Laczka C, Koblos G, Sarkadi B, and Varadi A. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition. Biochim Biophys Acta 2005; 1668:53-63.
37. Rabindran SK, Ross DD, Doyle LA, Yang W, and Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000; 60:47-50.
38. Karpova TS, Baumann CT, He L, Wu X, Grammer A, Lipsky P, Hager GL, and McNally JG. Fluorescence resonance energy transfer from cyan to yellow fluorescent protein detected by acceptor photobleaching using confocal microscopy and a single laser. J Microsc 2003; 209:56-70.
39. Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N, and Bates SE. Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 2004; 43:9448-9456.
40. Piston DW, and Kremers GJ. Fluorescent protein FRET: the good, the bad and the ugly, Trends Biochem Sci 2007; 32:407-414.